Optimizing outcomes for patients with gastric cancer peritoneal carcinomatosis

Table 1 Studies with positive cytology or low volume peritoneal carcinomatosis

Ref.	Patient No.	Treatment group(s)	Intraperitoneal regimen	Systemic regimen	Outcomes
Aizawa et al[17], 2015	47	NA systemic chemo	--	Variable	48.9% converted to negative cytology
					Negative cytology Median OS: 30.4 mo	Positive cytology Median OS: 15.0 mo
Badgwell et al[18], 2017	19	NA systemic chemo, then NLHIPEC, then gastrectomy if peritoneal disease cleared	MMC and cisplatin	Variable	36.8% converted to negative cytology or had clearance of PC Entire cohort median OS: 30.2 mo
Fujiwara et al[19], 2011	25	NA systemic and IP chemo → gastrectomy if peritoneal disease cleared	MMC and cisplatin	IV docetaxel, 5-fu, cisplatin	56% converted to negative cytology or had clearance of PC
					Negative Median OS: 27.1 mo	Positive Median OS: 9.6 mo
Ishigami et al[20], 2009	40	NA systemic and IP chemo	Paclitaxel	IV paclitaxel and oral S-1	Median OS: 22.5 mo

NA: Neoadjuvant; chemo: Chemotherapy; OS: Overall survival; NLHIPEC: Neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy; MMC: Mitomycin C; PC: Peritoneal carcinomatosis; IP: Intraperitoneal; IV: Intravenous; 5-FU: 5-fluorouracil.